Establishment Labs Holdings Inc. $ESTA Shares Sold by Rice Hall James & Associates LLC

Rice Hall James & Associates LLC decreased its stake in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 15.8% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 548,674 shares of the company’s stock after selling 102,885 shares during the period. Establishment Labs comprises about 1.7% of Rice Hall James & Associates LLC’s investment portfolio, making the stock its 11th biggest holding. Rice Hall James & Associates LLC’s holdings in Establishment Labs were worth $31,154,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Goldman Sachs Group Inc. grew its stake in Establishment Labs by 117.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 811,536 shares of the company’s stock worth $59,145,000 after purchasing an additional 438,206 shares in the last quarter. Viking Global Investors LP acquired a new stake in Establishment Labs during the second quarter valued at approximately $14,669,000. Soleus Capital Management L.P. acquired a new stake in Establishment Labs during the second quarter valued at approximately $9,050,000. Summit Partners Public Asset Management LLC lifted its holdings in Establishment Labs by 87.1% during the 3rd quarter. Summit Partners Public Asset Management LLC now owns 430,160 shares of the company’s stock worth $17,632,000 after buying an additional 200,255 shares during the last quarter. Finally, Nantahala Capital Management LLC lifted its holdings in Establishment Labs by 11.1% during the 3rd quarter. Nantahala Capital Management LLC now owns 1,973,492 shares of the company’s stock worth $80,893,000 after buying an additional 197,962 shares during the last quarter. 72.91% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Establishment Labs

In related news, Director Quiros Juan Jose Chacon sold 105,000 shares of the stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $75.42, for a total value of $7,919,100.00. Following the sale, the director owned 927,504 shares of the company’s stock, valued at $69,952,351.68. This trade represents a 10.17% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last 90 days, insiders have sold 182,180 shares of company stock valued at $13,369,722. 9.99% of the stock is owned by company insiders.

Establishment Labs Price Performance

Shares of ESTA opened at $92.32 on Friday. Establishment Labs Holdings Inc. has a 12 month low of $33.35 and a 12 month high of $96.99. The company has a debt-to-equity ratio of 16.82, a current ratio of 2.96 and a quick ratio of 1.91. The stock has a fifty day moving average price of $82.58 and a 200 day moving average price of $72.72. The company has a market cap of $2.72 billion, a P/E ratio of -61.96 and a beta of 1.06.

Establishment Labs (NASDAQ:ESTA) last posted its earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.10). Establishment Labs had a negative net margin of 19.05% and a negative return on equity of 218.77%. The company had revenue of $59.88 million during the quarter, compared to the consensus estimate of $57.40 million. During the same quarter in the previous year, the business posted ($0.70) earnings per share. The business’s quarterly revenue was up 44.7% compared to the same quarter last year. On average, research analysts forecast that Establishment Labs Holdings Inc. will post -1.07 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on ESTA. BTIG Research reiterated a “buy” rating on shares of Establishment Labs in a research report on Monday, July 13th. Citigroup upped their price target on Establishment Labs from $76.00 to $92.00 and gave the company a “neutral” rating in a research report on Wednesday, July 8th. TD Cowen restated a “buy” rating on shares of Establishment Labs in a research note on Monday, June 8th. Wall Street Zen downgraded shares of Establishment Labs from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Establishment Labs in a research note on Wednesday, June 24th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Establishment Labs has a consensus rating of “Moderate Buy” and a consensus target price of $90.43.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.